Study identifies clinical risk factors for chemotherapy-induced nerve toxicity

A cross-sectional multisite study of 901 individuals treated with neurotoxic cancer agents (taxanes, platinum, vinca alkaloids, bortezomib, thalidomide) assessed chemotherapy-induced peripheral neurotoxicity (CIPN) using clinical grading, neurologic evaluation, and patient-reported outcomes. The study reported that 37% had moderate-to-severe CIPN and 31% required dose modification due to CIPN, with female sex associated with dose-limiting CIPN, and older age, diabetes, higher BMI, and prior neurotoxic treatment associated with post-treatment and severe CIPN across assessment tools. The authors stated these are clinical variables available at treatment initiation that suggest increasing susceptibility to developing CIPN.

Most relevant for: Patients receiving neurotoxic chemotherapy agents such as taxanes, platinum compounds, vinca alkaloids, bortezomib, or thalidomide, particularly those with diabetes, higher BMI, older age, or prior neurotoxic treatment.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.